Ozanimod Controls MS Disease Activity Regardless of Age
WEST PALM BEACH, Fla. — Clinical and radiologic measures of disease activity remained stable or improved for relapsing multiple sclerosis (RMS) patients in all age groups over 7 to 8 years of continuous treatment with ozanimod (Zeposia). “Regardless of age category, the adjusted annualized relapse rate was below 0.2 in the phase III parent trials […]
Investigational Immunotherapy Combo Shows Promise for Advanced Solid Tumors
An investigational combination of CTLA-4 and PD‐1 checkpoint inhibitors demonstrated “encouraging” tumor activity, as well as a manageable safety profile, in patients with advanced/metastatic solid tumors, according to results from a small phase I study. Among 61 patients with different solid tumors who were evaluated for efficacy, 37.7% achieved an objective response to treatment with […]
Physical activity is insufficient to counter cardiovascular risk associated with sugar-sweetened beverage consumption
Contrary to popular belief, the benefits of physical activity do not outweigh the risks of cardiovascular disease associated with drinking sugar-sweetened beverages, according to a new study led by Harvard T.?H.?Chan School of Public Health. Jean-Philippe Drouin-Chartier, professor at Université Laval’s Faculty of Pharmacy, was a co-author. Sugar-sweetened beverages are the largest source of added […]
Combination Shows Promise in Metastatic ESR1-Mutant Breast Cancer
A novel drug combination led to clinically meaningful antitumor activity in metastatic ESR1-mutated, estrogen receptor-positive (ER+)/HER2-negative breast cancer that had progressed on CDK4/6 inhibition, a small prospective study showed. Adding the selective estrogen receptor modulator (SERM) lasofoxifene to abemaciclib (Verzenio) resulted in a median progression-free survival (PFS) of 56 weeks, and a 24-week clinical benefit […]
Progression Independent of Relapse Activity in Pediatric-Onset MS
Pediatric-onset multiple sclerosis (MS) patients showed progression independent of relapse activity (PIRA) even when they were relatively young, a prospective cohort study found. Confirmed PIRA events within 48 weeks of baseline occurred in 40.4% of pediatric-onset MS patients and were more frequent in older-onset groups, reported Maria Pia Amato, MD, of the University of Florence […]
Novel Brain Implants Help Paralyzed People Speak Faster, More Accurately
High-performance brain-computer interfaces (BCIs) decoded brain activity into speech faster, more accurately, and with a bigger vocabulary than existing technologies, two early trials in Nature showed. In the BrainGate2 study, speech-to-text BCI that recorded activity from intracortical microelectrode arrays (MEAs) decoded the speech of a woman with amyotrophic lateral sclerosis (ALS) at 62 words per […]
Brain Signals Reconstruct Pink Floyd Song
Brain recordings detected Pink Floyd. From the recorded activity of intracranial electroencephalography (EEG) electrodes placed on the brains of 29 epilepsy surgery patients, the phrase “all in all, it was just a brick in the wall” from Pink Floyd came through — its rhythm intact, its lyrics muffled yet decipherable, reported Ludovic Bellier, PhD, of […]
Are Athletes With T1D Putting Themselves at Risk for Recurrent Hypoglycemia?
CHICAGO – Nearly three-fourths of people with type 1 diabetes (T1D) who engaged in aerobic activity failed to follow guidelines for preventing hypoglycemia, according to a survey-based study. Guidelines state that if a person with T1D experiences severe hypoglycemia, they should not exercise for 24 hours, but 73% of those surveyed (n=102 adults) reported exercising […]
Immune Checkpoint Inhibitors Safe, Effective in Cancer Patients With HIV
Immune checkpoint inhibitors showed activity among people with HIV and various cancer types, without any excess or unexpected toxicities, according to a retrospective real-world study. In a cohort of 390 patients with HIV and cancer, 20% had immune-related adverse events (AEs) of any grade and 7.7% had grade ≥3 immune-related AEs, reported Abdul Rafeh Naqash, […]
Pembrolizumab Active in BCG-Unresponsive Papillary High-Risk Bladder Cancer
SAN FRANCISCO — Pembrolizumab (Keytruda) monotherapy showed encouraging antitumor activity in patients with papillary high-risk non-muscle-invasive bladder cancer (HR NMIBC) that was unresponsive to Bacillus Calmette-Guerin (BCG) treatment. In a cohort of patients in the KEYNOTE-057 study who had 45 months of follow-up, those treated with pembrolizumab (n=32) had an estimated 12-month disease-free survival (DFS) […]